Compare ASTRAZENECA PHARMA with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FRESENIUS KABI ONCO. ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 79.9 22.1 361.0% View Chart
P/BV x 24.2 3.1 777.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,278176 726.1%   
Low Rs88379 1,124.3%   
Sales per share (Unadj.) Rs228.437.7 606.1%  
Earnings per share (Unadj.) Rs10.45.1 203.5%  
Cash flow per share (Unadj.) Rs16.36.7 241.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.842.5 232.2%  
Shares outstanding (eoy) m25.00158.23 15.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.4 140.1%   
Avg P/E ratio x104.225.0 417.2%  
P/CF ratio (eoy) x66.418.9 351.0%  
Price / Book Value ratio x10.93.0 365.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,00820,135 134.1%   
No. of employees `0001.41.2 117.7%   
Total wages/salary Rs m1,535703 218.3%   
Avg. sales/employee Rs Th4,210.95,176.2 81.4%   
Avg. wages/employee Rs Th1,132.2610.4 185.5%   
Avg. net profit/employee Rs Th191.1699.6 27.3%   
INCOME DATA
Net Sales Rs m5,7105,963 95.8%  
Other income Rs m12318 680.6%   
Total revenues Rs m5,8335,981 97.5%   
Gross profit Rs m4631,430 32.4%  
Depreciation Rs m147258 57.2%   
Interest Rs m0-26 0.0%   
Profit before tax Rs m4381,216 36.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m179342 52.3%   
Profit after tax Rs m259806 32.2%  
Gross profit margin %8.124.0 33.8%  
Effective tax rate %40.828.1 145.2%   
Net profit margin %4.513.5 33.6%  
BALANCE SHEET DATA
Current assets Rs m3,2095,102 62.9%   
Current liabilities Rs m2,0702,385 86.8%   
Net working cap to sales %20.045.6 43.8%  
Current ratio x1.62.1 72.5%  
Inventory Days Days72150 48.2%  
Debtors Days Days35113 30.8%  
Net fixed assets Rs m7905,148 15.4%   
Share capital Rs m50158 31.6%   
"Free" reserves Rs m2,4196,556 36.9%   
Net worth Rs m2,4696,732 36.7%   
Long term debt Rs m0952 0.0%   
Total assets Rs m4,60510,388 44.3%  
Interest coverage xNM-45.8-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.20.6 216.0%   
Return on assets %5.67.5 74.9%  
Return on equity %10.512.0 87.6%  
Return on capital %17.714.6 121.5%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m3005,298 5.7%   
Fx outflow Rs m2,0151,772 113.7%   
Net fx Rs m-1,7153,525 -48.7%   
CASH FLOW
From Operations Rs m881,274 6.9%  
From Investments Rs m-94-1,204 7.8%  
From Financial Activity Rs mNA-196 0.0%  
Net Cashflow Rs m-6-126 4.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 15.7 9.6 163.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   12,856 42,599 30.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 1,028 Points; Oil & Gas, FMCG and Metal Stocks Rally(Closing)

Indian share markets continued to trade in the green during closing hours and ended their day on a strong note, tracking global cues.

Related Views on News

SYNGENE INTERNATIONAL Surges by 7%; BSE HEALTHCARE Index Up 3.4% (Market Updates)

Mar 31, 2020 | Updated on Mar 31, 2020

SYNGENE INTERNATIONAL share price has surged by 7% and its current market price is Rs 245. The BSE HEALTHCARE is up by 3.4%. The top gainers in the BSE HEALTHCARE Index are SYNGENE INTERNATIONAL (up 6.7%) and ASTRAZENECA PHARMA (up 7.7%). The top losers are BLISS GVS PHARMA and NATCO PHARMA (down 0.3%).

SUN PHARMA Surges by 5%; BSE HEALTHCARE Index Up 3.5% (Market Updates)

Mar 31, 2020 | Updated on Mar 31, 2020

SUN PHARMA share price has surged by 5% and its current market price is Rs 351. The BSE HEALTHCARE is up by 3.5%. The top gainers in the BSE HEALTHCARE Index are SUN PHARMA (up 5.2%) and ASTRAZENECA PHARMA (up 8.0%). The top losers are THYROCARE TECHNOLOGIES (down 0.1%) and BIOCON (down 0.6%).

DIVIS LABORATORIES Surges by 5%; BSE HEALTHCARE Index Up 3.2% (Market Updates)

Mar 31, 2020 | Updated on Mar 31, 2020

DIVIS LABORATORIES share price has surged by 5% and its current market price is Rs 1,989. The BSE HEALTHCARE is up by 3.2%. The top gainers in the BSE HEALTHCARE Index are DIVIS LABORATORIES (up 5.0%) and ASTRAZENECA PHARMA (up 7.4%). The top losers are DR. LAL PATHLABS LTD (down 1.0%) and BIOCON (down 1.0%).

CAPLIN POINT Surges by 7%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Mar 31, 2020 | Updated on Mar 31, 2020

CAPLIN POINT share price has surged by 7% and its current market price is Rs 280. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index are CAPLIN POINT (up 7.0%) and ASTRAZENECA PHARMA (up 5.0%). The top losers are SUN PHARMA (down 0.8%) and DR. LAL PATHLABS LTD (down 0.9%).

PIRAMAL ENTERPRISES Surges by 7%; BSE HEALTHCARE Index Up 1.9% (Market Updates)

Mar 31, 2020 | Updated on Mar 31, 2020

PIRAMAL ENTERPRISES share price has surged by 7% and its current market price is Rs 937. The BSE HEALTHCARE is up by 1.9%. The top gainers in the BSE HEALTHCARE Index are PIRAMAL ENTERPRISES (up 6.9%) and ASTRAZENECA PHARMA (up 5.3%). The top losers are NATCO PHARMA (down 0.6%) and SUN PHARMA (down 0.6%).

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Mar 31, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS